Monte Rosa Therapeutics, Inc. GLUE Invested capital
Discontinued — last reported Q1 '26
Invested capital at other companies
Other financials
Where this comes from
Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s invested capital?
- Monte Rosa Therapeutics, Inc. (GLUE) reported invested capital of $401.12M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s invested capital changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s invested capital increased by 68.2% year-over-year, from $238.49M to $401.12M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s invested capital?
- Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s invested capital has grown at a 100.3% compound annual growth rate (CAGR), from $8.84M to $142.36M.
- What does invested capital mean?
- Total debt plus shareholders' equity minus cash, at the quarter end. The capital actually put to work in the operating business — the denominator of return on invested capital (ROIC).